NCT05676372

Brief Summary

Single cell transcriptomics of CRC PC samples

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 16, 2020

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

November 26, 2020

Completed
2.1 years until next milestone

First Posted

Study publicly available on registry

January 9, 2023

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

December 28, 2023

Status Verified

December 1, 2023

Enrollment Period

5.5 years

First QC Date

November 26, 2020

Last Update Submit

December 27, 2023

Conditions

Peritoneal Metastases

Outcome Measures

Primary Outcomes (1)

  • Single-cell transcriptomics

    A transcriptional single-cell RNA seq atlas of gene expression data will be reported

    24 months

Interventions

CRC+HIPECPROCEDURE

Sample prelevation of cytoreductive surgery

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing CRS+HIPEC

You may qualify if:

  • Patients undergoing CRS+HIPEC for PC of colorectal origin

You may not qualify if:

  • Previous HIPEC/PIPAC

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UZ Ghent

Ghent, Oost-Vlaanderen, 9000, Belgium

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Peritoneal metastases (surgical waste material)

Study Officials

  • Wim Ceelen, MD, PhD

    UZ Ghent

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Wim P Ceelen, MD, PhD

CONTACT

093326251wim.ceelen@ugent.be

Jesse G Demuytere, MD

CONTACT

093324278jesse.demuytere@ugent.be

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 26, 2020

First Posted

January 9, 2023

Study Start

June 16, 2020

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

December 28, 2023

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations

BE(1)